Paris saponin I induces apoptosis via increasing the Bax/Bcl‑2 ratio and caspase‑3 expression in gefitinib‑resistant non‑small cell lung cancer in vitro and in vivo

  • Authors:
    • Hao Jiang
    • Peng‑Jun Zhao
    • Dan Su
    • Jianguo Feng
    • Sheng‑Lin Ma
  • View Affiliations

  • Published online on: April 2, 2014     https://doi.org/10.3892/mmr.2014.2108
  • Pages: 2265-2272
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Polyphyllins, a major component of Rhizoma paridis, have been extensively used in non‑small cell lung cancer (NSCLC). The aim of the present study was to evaluate the effects of Paris saponin I (PSI) on a panel of gefitinib‑resistant NSCLC cell lines and its inhibition of tumor growth in a nude mouse model. The MTT assay was used to assess growth inhibition. The cell cycle was analyzed using flow cytometry and apoptosis was assessed using Annexin V/propidium iodide staining. The morphology of the apoptotic cells was determined by transmission electron microscopy. The protein expression levels of B‑cell lymphoma 2 (Bcl‑2), Bcl‑2‑associated X protein (Bax) and caspase‑3 were detected using western blot analysis. In addition, the glucose metabolism in tumor‑bearing mice was evaluated using 18F‑fludeoxyglucose (FDG) micro‑positron emission tomography imaging. The PSI‑induced growth inhibition rate was observed to significantly increase in a time‑ and dose‑dependent manner. Furthermore, PSI induced significant G2/M‑phase arrest and apoptosis. The expression levels of Bcl‑2 decreased, while those of Bax and caspase‑3 increased following PSI treatment. 18F‑FDG‑uptake in the PSI treatment groups was significantly decreased compared with that in the control group in vivo. In conclusion, PSI is a potent antitumor agent that acts by inhibiting the proliferation of gefitinib‑resistant cells, and has potential as a candidate for a natural drug for gefitinib‑resistant therapy. PSI‑induced apoptosis, which occurred via multiple pathways, including G2/M‑phase arrest and upregulation of the Bax/Bcl‑2 ratio and caspase‑3 expression, ultimately led to cell death and tumor inhibition.
View Figures
View References

Related Articles

Journal Cover

June 2014
Volume 9 Issue 6

Print ISSN: 1791-2997
Online ISSN:1791-3004

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Jiang, H., Zhao, P., Su, D., Feng, J., & Ma, S. (2014). Paris saponin I induces apoptosis via increasing the Bax/Bcl‑2 ratio and caspase‑3 expression in gefitinib‑resistant non‑small cell lung cancer in vitro and in vivo. Molecular Medicine Reports, 9, 2265-2272. https://doi.org/10.3892/mmr.2014.2108
MLA
Jiang, H., Zhao, P., Su, D., Feng, J., Ma, S."Paris saponin I induces apoptosis via increasing the Bax/Bcl‑2 ratio and caspase‑3 expression in gefitinib‑resistant non‑small cell lung cancer in vitro and in vivo". Molecular Medicine Reports 9.6 (2014): 2265-2272.
Chicago
Jiang, H., Zhao, P., Su, D., Feng, J., Ma, S."Paris saponin I induces apoptosis via increasing the Bax/Bcl‑2 ratio and caspase‑3 expression in gefitinib‑resistant non‑small cell lung cancer in vitro and in vivo". Molecular Medicine Reports 9, no. 6 (2014): 2265-2272. https://doi.org/10.3892/mmr.2014.2108